Cargando…
Next generation therapies change the landscape in melanoma
Melanoma is among the leading causes of years of life lost due to cancer. Current chemotherapy and cytokine-based immunotherapy approaches benefit only a small percentage of patients with advanced disease. However, the recent discovery of mutations in the gene encoding the serine-threonine kinase B-...
Autor principal: | Flaherty, Keith T. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Faculty of 1000 Ltd
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096880/ https://www.ncbi.nlm.nih.gov/pubmed/21654923 http://dx.doi.org/10.3410/M3-8 |
Ejemplares similares
-
Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape
por: Srivastava, Neeharika, et al.
Publicado: (2014) -
Next generation sequencing technologies and the changing landscape of phage genomics
por: Klumpp, Jochen, et al.
Publicado: (2012) -
The Clinical Trial Landscape for Melanoma Therapies
por: Wróbel, Sonia, et al.
Publicado: (2019) -
Applying next-generation sequencing to unravel the mutational landscape in viral quasispecies
por: Lu, I-Na, et al.
Publicado: (2020) -
Genetic Landscape and Emerging Therapies in Uveal Melanoma
por: Seedor, Rino S., et al.
Publicado: (2021)